Medicines for the treatment of advanced breast cancer and ADHD are among those to have been approved for use by the NHS in Scotland.
The Scottish Medicines Consortium (SMC) announced it has accepted five new drugs for routine use in the health service.
Charities welcomed the move to offer Fulvestrant, known as Faslodex, as a "huge relief" for people living with incurable secondary breast cancer.
Nicolas White, head of Scotland at Breast Cancer Care, said: "It is welcome news after four drugs for the disease have been consecutively declined.
"Women we support tell us over and over that they long for extra time with their loved ones - time which these life-extending drugs can give.
"This decision will give patients with limited treatment options a much-needed ray of hope."
Among the other medicines being approved was Panobinostat, or Farydak, which is used to treat multiple myeloma - a rare cancer of the white blood cells. It offers a further treatment option to patients who have received at least two prior treatments.
Guanfacine hydrocholoride (Intuniv) was accepted for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents aged six to 17.
The committee also gave the green light for ulipristral acetate (Esmya) for treating uterine fibroids and golimumab, or Simponi, for axial spondyloarthritis, an inflammatory arthritis that affects the spine and joints that lie at the junction of the spine and pelvis.
SMC chairman Professor Jonathan Fox said: "We are pleased to be able to accept five new medicines and hope that patients and their families will benefit from these decisions.
"We were disappointed that we were unable to accept eculizumab for routine use in aHUS (atypical Haemolytic Uraemic Syndrome). The committee recognised the benefits it provides for patients with this condition.
"While the Pace (Patient and Clinician Engagement) process gives the committee additional flexibility in order to increase access to medicines used at the end of life and for very rare conditions, that access cannot come at any price - we have to consider value for money and take account of the needs of all patients who need treatment, not only those affected by the condition under consideration.
"We understand that this decision will be very disappointing for patients. We would welcome a resubmission for eculizumab that takes into account the issues raised by the SMC appraisal."
Why are you making commenting on The Herald only available to subscribers?
It should have been a safe space for informed debate, somewhere for readers to discuss issues around the biggest stories of the day, but all too often the below the line comments on most websites have become bogged down by off-topic discussions and abuse.
heraldscotland.com is tackling this problem by allowing only subscribers to comment.
We are doing this to improve the experience for our loyal readers and we believe it will reduce the ability of trolls and troublemakers, who occasionally find their way onto our site, to abuse our journalists and readers. We also hope it will help the comments section fulfil its promise as a part of Scotland's conversation with itself.
We are lucky at The Herald. We are read by an informed, educated readership who can add their knowledge and insights to our stories.
That is invaluable.
We are making the subscriber-only change to support our valued readers, who tell us they don't want the site cluttered up with irrelevant comments, untruths and abuse.
In the past, the journalist’s job was to collect and distribute information to the audience. Technology means that readers can shape a discussion. We look forward to hearing from you on heraldscotland.com
Comments & Moderation
Readers’ comments: You are personally liable for the content of any comments you upload to this website, so please act responsibly. We do not pre-moderate or monitor readers’ comments appearing on our websites, but we do post-moderate in response to complaints we receive or otherwise when a potential problem comes to our attention. You can make a complaint by using the ‘report this post’ link . We may then apply our discretion under the user terms to amend or delete comments.
Post moderation is undertaken full-time 9am-6pm on weekdays, and on a part-time basis outwith those hours.
Read the rules here